PREPrenetics Global Limited
$17.42+6.8% 1Y
$17.42
$11.7952 weeks$26.30
Is the business good?
How good a business is PRE?
Prenetics Global Limited earns −38% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−38%
Return on invested capital · cost of capital 9.0% · 47 points below what the capital costs: growth destroys value
- Operating margin
- −48%
Operating margin · Diagnostics & Research median 3.6% · fiscal year to FY2025
- Share count, year on year
- +12%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 5.5%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −1.5% |
| FY2021 | −452% |
| FY2022 | −502% |
| FY2023 | −177% |
| FY2024 | −228% |
| FY2025 | −48% |
Details›
- Gross marginfiscal year to FY2025
- 53%
- Operating marginfiscal year to FY2025
- −48%
- Net marginfiscal year to FY2025
- −41%
- Free cash flow margin
- −24%
- R&D as % of revenue
- 5.5%
- Revenue, trailing twelve months
- $92M
- Free cash flow, trailing twelve months
- −$22M
- Net income, trailing twelve months
- −$38M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −38%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Diagnostics & Research
Ranks #19 of 21 by RyuScore